Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Melanoma

Skin Neoplasms

Neoplasm Metastasis

Nevus

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevi and Melanomas

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Vaccines

Immunomodulating Agents

Allovectin-7®

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.

Treatment - If you take part in this trial you will be treated for about 10 weeks. You will receive an injection of Allovectin-7® by needle, directly into one or more selected tumors once a week for the first six weeks. The injections may be given in a doctor's office. During a four-week observation period, your disease will be measured to see if the treatment is working. This will be done by general physical exams and scans (such as X-ray scans). Patients who show no sign of disease progression may be offered an option to repeat this treatment course.

Phase II Trial of Allovectin-7® for Metastatic Melanoma

A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma

Vical

Dmitri D. Kharkevitch, MD, PhD

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Carcinoma

Carcinoma, Squamous Cell

Head and Neck Neoplasms

Laryngeal Diseases

Otorhinolaryngologic Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms, Squamous Cell

Oral Squamous Cell Carcinoma

Tongue Cancer

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

Treatment - If you take part in this trial you will be treated for about four weeks. You will receive an injection of Allovectin-7® by needle, directly into your tumor. This will be repeated 14 days later. The injections may be given in a doctor's office. A week later, you will undergo surgery to remove the tumor. Your tumor will be measured before Allovectin-7® treatment and before surgery to see if Allovectin-7® was effective in shrinking it. This will be done by general physical exams and scans (such as X-ray scans). There will also be tests on the removed tumor to see if Allovectin-7® helped to boost the immune system to attack the cancer.

Phase II Trial of Allovectin-7® for Head and Neck Cancer

Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Ya-Ying Bai, M.S.

Chih-Hsin Yang, M.D., Ph.D.

Jih-Hsiang Lee, M.D.

Chong-Jen Yu, M.D., Ph.D.

Jin-Yuan Shih, M.D., Ph.D.

Chao-Chi Ho, M.D., Ph.D.

Wei-Yu Liao, M.D.

Kuan-Yu Chen, M.D., Ph.D.

Chia-Chi Lin, M.D., Ph.D.

Yu-Lin Lin, M.D.

Chih-Hsin Yang, M.D., ph.D.

To compare the frequency of individual genetic abnormality between tumor cells and blood specimens.

Samples will be collected before the systemic therapy. After initiation of therapy, samples will be collected at end of the 1st month, at the end of the 2nd month at the end of 3rd months and once every three months thereafter concurrently with the tumor assessment such as time of performing CT scans. In selected consented patients, peripheral blood samples will be collected every week for the first month.

Disease status will be assessed every 2\~3 months and at the end of treatment according to RECIST criteria. If progression is not observed at the end of therapy, patients will be assessed every 3 months until progression or further anti-cancer therapy. Progression-free survival, overall survival and response rate will be reported.

Gene Mutations in Non-Small Cell Lung Cancer Cells

Detection of Gene Mutations in Non-small Cell Lung Cancer Cells in Blood Samples or Fine-needle Aspiration

National Taiwan University Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Phase II Trial of Allovectin-7® for Metastatic Melanoma	NCT00044356	Melanoma Metastatic Mela... Malignant Melan... Skin Cancer	Allovectin-7®	18 Years -	Vical
Phase II Trial of Allovectin-7® for Head and Neck Cancer	NCT00050388	Head and Neck C... Squamous Cell C... Head and Neck N... Carcinoma of th...	Allovectin-7®	18 Years -	Vical
Gene Mutations in Non-Small Cell Lung Cancer Cells	NCT00977509	Carcinoma, Non-...		20 Years -	National Taiwan University Hospital

Spots Global Cancer Trial Database for cancer cells

Every month we try and update this database with for cancer cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.